Biophytis Secures Funding for Obesity Trial in Brazil

Biophytis SA has announced significant progress in its OBA Phase 2 trial focusing on muscle wasting associated with obesity. The company's Brazilian subsidiary has secured public funding from EMBRAPII, a government-backed innovation agency, for the trial. Additionally, Biophytis has signed agreements with FARMAVAX-UFMG and FMRP-USP, two leading obesity medical research centers in Brazil, to enhance clinical research capabilities.

The trial, which plans to recruit 122 out of 164 patients in Brazil, will leverage the country's expertise in obesity and metabolic disorders. The partnerships will provide Biophytis with access to a large patient pool and high-quality clinical research infrastructure. These developments are expected to enhance data generation and recruitment efficiency.

The support from EMBRAPII represents a non-dilutive funding opportunity, reducing the financial burden on Biophytis while underscoring the trial's national significance. For investors, this development may strengthen the trial's credibility and potential market impact.